AP 1531

Drug Profile

AP 1531

Alternative Names: BGC-20-1531; PGN-1531

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asterand plc
  • Developer BTG
  • Class Antimigraines
  • Mechanism of Action Prostaglandin E4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 23 Feb 2016 Discontinued - Phase-I for Migraine in United Kingdom (PO)
  • 12 Jan 2016 BTG withdraw a phase II trial in Migraine in Denmark, Norway and United Kingdom (NCT00888680)
  • 21 Sep 2011 AP 1531 licensed to Ariel Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top